Results 161 to 170 of about 374,365 (198)
Some of the next articles are maybe not open access.
Removing the black box warning for depot medroxyprogesterone acetate
Contraception, 2011This commentary explains why the Food and Drug Administration (FDA) should remove the black box warning regarding skeletal health on the package labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA). It states that by depriving women of long-term use of this safe effective product this black box warning hurts the public ...
Andrew M, Kaunitz, David A, Grimes
openaire +2 more sources
Depot Medroxyprogesterone Acetate and Breast Cancer
Drug Safety, 1996Depot medroxyprogesterone acetate (DMPA) has been used worldwide since 1964 as a contraceptive and by 1993 was in use in more than 90 countries. It was licensed for contraceptive use in the US in 1992. One of the reasons for this delay in licensing in the US was the possibility of an increased risk of breast cancer associated with its use.
openaire +2 more sources
Depot Medroxyprogesterone Acetate and Breast Cancer
JAMA, 1995Background. —Although depot medroxyprogesterone acetate (DMPA) (Depo-Provera) has now been approved for marketing as a contraceptive in the United States, there are still unresolved issues about the relation between DMPA and risk of breast cancer. The two substantial case-control studies of this association yielded similar but inconclusive results ...
openaire +1 more source
Depot Medroxyprogesterone Acetate or Oral Contraception in Postpartum Adolescents
Obstetrics & Gynecology, 1998To compare rates of method continuation and repeat pregnancy among postpartum adolescents selecting depot medroxyprogesterone acetate or oral contraceptives (OCs).A retrospective study of 161 adolescents aged 19 years and younger who gave birth at an urban teaching hospital between May 1, 1994, and April 30, 1995, returned to the hospital's family ...
C M, O'Dell +4 more
openaire +2 more sources
Anaphylaxis From Depot Medroxyprogesterone Acetate in an Adolescent Girl
Obstetrics & Gynecology, 2011Anaphylaxis postinjection of depot medroxyprogesterone acetate (DMPA) has been rarely reported in adult women.A 16-year-old girl developed anaphylaxis after receiving 150 mg of DMPA intramuscularly. She previously had received four injections of DMPA without any adverse reactions, including two earlier doses from the same lot number.
Lisa, Lestishock +3 more
openaire +2 more sources
Premenopausal bone loss and depot medroxyprogesterone acetate administration
International Journal of Gynecology & Obstetrics, 1994A 39-year-old woman on depot medroxyprogesterone acetate for 17 years developed multiple fractures after falling from a stationary horse. Densitometry revealed significant osteopenia. Although the reported patient was a thin, Caucasian woman, she did not have any other significant risk factors for osteoporosis except for a possible state of partial ...
openaire +2 more sources
Long-acting injectable contraception with depot medroxyprogesterone acetate
American Journal of Obstetrics and Gynecology, 1994Depot medroxyprogesterone acetate (DMPA) is the only injectable contraceptive available in the United States. After more than 20 years of regulatory review, the Food and Drug Administration approved DMPA for contraceptive use in 1992 after the publication of reassuring data about its possible association with breast cancer.
openaire +2 more sources
Bone Density in Long Term Users of Depot Medroxyprogesterone Acetate
Obstetrical & Gynecological Survey, 1998Objective To identify any adverse effect on bone density in long term users of depot medroxyprogesterone acetate (DMPA) for contraception.Design Cross‐sectional measurement of bone density in users with amenorrhoea of more than one year or any woman using DMPA for more than five years.Setting Community Family Planning Clinics in ...
B, Gbolade +4 more
openaire +2 more sources
Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism
Contraception, 1991To assess the effects of depot-medroxyprogesterone acetate (DMPA) upon serum lipids and lipoproteins, a comparative study in chronic users and new acceptors was undertaken. Two groups of women of reproductive age were included in the study; group I (n = 8) was formed by new acceptors whereas, group II (n = 14) constituted DMPA users of more than five ...
J, Garza-Flores +6 more
openaire +2 more sources
Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary
Contraception, 1994This review addresses possible associations between depot-medroxy-progesterone acetate (DMPA) and endometrial and epithelial ovarian cancers. Two unexpected endometrial carcinomas were observed at autopsy of rhesus monkeys treated for 10 years with 50 times the human doses of DMPA.
openaire +2 more sources